한글목차

세계 요실금 치료제 시장의 미래는 병원 약국, 소매 약국, 온라인 약국 시장의 기회로 인해 유망합니다. 세계 요실금 치료제 시장은 2025-2031년 연평균 복합 성장률(CAGR) 4.3%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 노인 인구 증가로 인한 요실금 치료 수요 증가, 요실금에 대한 인식 증가로 인한 치료법 채택 촉진, 약물 개발의 발전으로 인한 효과 및 환자 결과 개선입니다.

• Lucintel의 예측에 따르면, 유형별로는 진경제가 요실금 치료에 효과적이기 때문에 예측 기간 동안 가장 높은 성장률을 보일 것으로 예측됩니다.
• 용도별로는 편의성, 접근성, 디지털 도입 증가로 인해 온라인 약국이 가장 높은 성장세를 보일 것으로 예측됩니다.
• 지역별로는 아시아태평양이 노인 인구 증가와 의료 서비스 접근성 향상으로 인해 예측 기간 동안 가장 높은 성장세를 보일 것으로 예측됩니다.

요실금 치료제 시장의 새로운 트렌드

요실금 치료제 시장은 새로운 약제군의 도입, 기술 발전, 개인 맞춤형 치료의 중요성 등 새로운 트렌드에 따라 빠르게 진화하고 있습니다. 이러한 추세는 환자들에게 더 많은 치료 옵션을 제공하고 삶의 질을 향상시킴으로써 시장의 판도를 바꾸고 있습니다.

• 신규 약제군별: 기존의 항콜린제를 대체할 수 있는 새로운 약제군으로 β3 작용제(미라베글론 등)와 같은 새로운 약제군이 등장하고 있습니다. 이 약제들은 효능이 개선되고 부작용이 감소하고 있습니다. 더 많은 치료법이 도입됨에 따라 시장은 더욱 다양해져 환자에게 요실금 관리를 위한 더 나은 선택권을 제공합니다.
• 병용요법: 경구용 약물과 행동치료와 같은 비약리학적 방법을 포함한 병용요법이 점점 더 선호되고 있습니다. 이 방법은 환자를 잘 관리하고 요실금을 개선하기 위한 전반적인 치료를 하는 데 도움이 됩니다.
• 개인 맞춤형 치료: 치료에 대한 개인별 반응에 대한 이해가 깊어짐에 따라 개인 맞춤형 의료로의 전환이 진행되고 있습니다. 연령, 생활습관, 기저질환 등의 요소에 기반한 맞춤 치료 계획은 환자가 증상을 보다 효과적으로 관리하고 치료 요법 순응도를 높일 수 있도록 돕습니다.
• 약물 전달 기술의 발전: 약물 전달 기술의 발전에는 서방형 제제, 경피 흡수 패치 등 약물 치료 순응도를 향상시키는 약물 전달 기술의 발전이 포함됩니다. 새로운 전달 시스템은 부작용을 최소화하고 환자가 증상을 느끼지 않는 시간을 연장하여 치료 계획의 순응도를 높일 수 있도록 돕습니다.
• 삶의 질에 대한 관심 증가: 시장에서는 환자의 QOL(삶의 질) 향상에 대한 관심이 높아지고 있습니다. 제약사들은 증상 관리뿐만 아니라 구강 건조, 변비 등의 부작용을 완화하는 약물을 개발하여 요실금 환자들에게 더 나은 전반적인 치료 경험을 제공합니다.

요실금 치료제 시장은 새로운 약물 계열별, 병용요법, 맞춤 치료 접근법, 약물 전달 기술 발전, 삶의 질 중시 등의 새로운 트렌드가 요실금 치료제 시장을 크게 형성하고 있습니다. 이러한 추세는 환자 치료를 개선하고 요실금 환자들에게 다양한 치료 옵션을 제공함으로써 요실금 환자들에게 더 나은 치료 옵션을 제공합니다.

요실금 치료제 시장의 최근 동향

요실금 치료제 시장의 최근 동향은 보다 효과적인 치료법의 도입, 약물의 다양화, 환자 중심의 치료 접근 방식으로 이어지고 있습니다. 이러한 개발은 과민성 방광과 스트레스성 요실금 관리를 위한 새로운 솔루션을 제공함으로써 시장을 재편하고 있습니다.

• 베타3 작용제 승인: 미라베글론과 같은 베타3 작용제의 승인으로 과민성 방광(OAB)에 대한 새로운 치료군이 도입되었습니다. 이들 치료제는 기존 항콜린제 대비 부작용이 적어 환자의 치료 요법 순응도를 높이고 질병을 더 잘 조절할 수 있도록 도와줍니다.
• 병용요법: 항콜린제와 다른 치료법과의 병용요법이 주목받고 있습니다. 이러한 치료법은 환자에게 보다 효과적이고 종합적인 관리 옵션을 제공하고, 여러 증상을 동시에 해결하며, 전반적인 치료 결과를 개선할 수 있습니다.
• 비경구 요법: 경피 패치나 주사 요법을 포함한 비경구 치료는 현재 경구용 약물을 대체할 수 있는 치료법으로 빠르게 부상하고 있습니다. 이러한 치료법은 복약 순응도가 좋고, 효과가 길며, 부작용이 적기 때문에 환자들에게 매우 매력적인 치료법입니다.
• 개인 맞춤형 의료에 대한 관심 증가: 개인 맞춤형 의료의 추진은 요실금 치료제 시장의 주요 발전입니다. 개인의 증상, 동반 질환, 생활습관 요인에 따라 치료 계획을 맞춤화함으로써 개인 맞춤형 의료는 치료 결과를 개선하고 환자가 가장 적합한 치료를 받을 수 있도록 돕습니다.
• 요실금에 대한 인식과 교육 증가: 요실금에 대한 인식과 교육이 높아지면서 치료 수요를 촉진하고 있습니다. 의료 서비스 제공업체들은 환자들에게 가능한 치료법에 대해 적극적으로 교육하고 있으며, 이로 인해 더 많은 환자들이 치료를 받게 되어 요실금 치료제 시장이 확대되고 있습니다.

베타3 작용제의 도입, 병용요법, 비경구 치료, 개인 맞춤형 치료, 인식 개선 등 주요 발전은 요실금 치료제 시장에 큰 영향을 미치고 있습니다. 이러한 기술 혁신은 요실금 환자들의 치료 결과를 향상시키고 치료 접근성을 개선하고 있습니다.

목차

제1장 주요 요약

제2장 세계의 요실금 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 요실금 치료제 시장 동향(2019-2024년)과 예측(2025-2031년)
• 유형별
  • 경련 진정제
  • 골격근 이완제
  • 알파 차단제
  • 기타
• 용도별
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별
  • 용도별
  • 지역별
• 세계의 요실금 치료제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 요실금 치료제 시장 캐파시티 확대
  • 세계 요실금 치료제 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Pfizer
• Astellas Pharma
• Allergan
• Merck & Co.
• Sanofi
• Medtronic
• Mylan

영문목차

The future of the global urinary incontinence drug market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets. The global urinary incontinence drug market is expected to grow with a CAGR of 4.3% from 2025 to 2031. The major drivers for this market are growing elderly population increases demand for urinary incontinence treatments, rising awareness of urinary incontinence drives treatment adoption, and advancements in drug development improve efficacy and patient outcomes.

• Lucintel forecasts that, within the type category, antispasmodic agent is expected to witness the highest growth over the forecast period due to their effectiveness in treating urinary incontinence.
• Within the application category, online pharmacies is expected to witness the highest growth due to convenience, accessibility, and growing digital adoption.
• In terms of region, APAC is expected to witness the highest growth over the forecast period due to increasing elderly population and healthcare access.

Emerging Trends in the Urinary Incontinence Drug Market

The urinary incontinence drug market is experiencing rapid evolution with emerging trends, including the introduction of novel drug classes, technological advancements, and the focus on personalized care. These trends are reshaping the landscape, offering patients more treatment options and improving their quality of life.

• Novel Drug Classes: New drug classes, such as beta-3 agonists (e.g., mirabegron), are emerging as alternatives to traditional anticholinergics. These drugs offer improved efficacy and a reduced side-effect profile. As more treatments are introduced, the market is becoming more diverse, providing patients with better options for managing urinary incontinence.
• Combination Therapies: Combination therapies, which would include oral medicines and nonpharmacological techniques such as behavior therapy, have become increasingly favored. This method helps in managing the patient well and provides holistic treatment for improving urinary incontinence.
• Personalized Treatment: With a better understanding of individual responses to treatments, there is an increasing shift toward personalized medicine. Personalized treatment plans, guided by factors like age, lifestyle, and underlying health conditions, can help patients manage symptoms more effectively and improve compliance with treatment regimens.
• Technological Advancements in Drug Delivery: Advances in drug delivery technology include extended-release formulations and transdermal patches, all of which have improved adherence to drug regimens. New delivery systems help to minimize side effects and prolong the time patients can go without their symptoms, thereby increasing compliance with treatment plans.
• Rising Focus on Quality of Life: The market is increasingly focusing on improving patients' quality of life. Pharmaceutical companies are developing drugs that not only manage the condition but also reduce side effects like dry mouth or constipation, offering a better overall treatment experience for patients with urinary incontinence.

Emerging trends such as novel drug classes, combination therapies, personalized treatment approaches, technological advancements in drug delivery, and a focus on quality of life are significantly shaping the urinary incontinence drug market. These trends are improving patient care and offering a broader range of treatment options for individuals living with urinary incontinence.

Recent Developments in the Urinary Incontinence Drug Market

Recent developments in the urinary incontinence drug market have led to the introduction of more effective treatments, greater drug variety, and a more patient-centric approach to care. These developments are reshaping the market by providing new solutions for managing both overactive bladder and stress urinary incontinence.

• Approval of Beta-3 Agonists: The approval of beta-3 agonists such as mirabegron has introduced a new treatment class for overactive bladder (OAB). These drugs have fewer side effects compared to traditional anticholinergics, improving patient adherence to treatment regimens and offering better disease control.
• Combination Therapies: Combination therapies, including anticholinergics with other treatment modalities, are gaining attention. These therapies provide patients with more effective and comprehensive management options, addressing multiple symptoms simultaneously and improving the overall treatment outcomes.
• Non-Oral Therapies: The non-oral treatments, which include transdermal patches and injectable therapies, are now fast emerging to serve as replacements for oral medication. Such therapies offer better drug adherence, longer effects, and fewer adverse effects, making them very appealing to patients.
• Increased Focus on Personalized Medicine: The push towards personalized medicine is a key development in the urinary incontinence drug market. By tailoring treatment plans to an individual's specific symptoms, comorbidities, and lifestyle factors, personalized medicine improves outcomes and ensures that patients receive the most appropriate therapy.
• Greater Awareness and Education: Increased awareness and education on urinary incontinence are driving demand for treatments. Healthcare providers are actively educating patients on the available therapies, which is helping more individuals seek treatment, ultimately expanding the market for urinary incontinence drugs.

These key developments, including the introduction of beta-3 agonists, combination therapies, non-oral treatments, personalized care, and increased awareness, are significantly impacting the urinary incontinence drug market. These innovations are enhancing treatment outcomes and improving access to care for those suffering from urinary incontinence.

Strategic Growth Opportunities in the Urinary Incontinence Drug Market

The urinary incontinence drug market offers significant growth opportunities, especially in areas such as emerging markets, drug delivery innovations, and targeted treatments. These opportunities allow pharmaceutical companies to expand their reach and provide improved solutions for the growing number of people experiencing urinary incontinence.

• Expansion into Emerging Markets: As awareness of urinary incontinence increases in emerging markets, there is significant growth potential for pharmaceutical companies. Countries like China and India, where the aging population is rising, offer untapped opportunities for companies to introduce their treatments and address local healthcare needs.
• Development of Non-Oral Drug Delivery Systems: Non-oral drug delivery systems, such as transdermal patches, extended-release tablets, and injectable therapies, offer a unique opportunity for growth. These systems provide greater convenience, improved adherence, and fewer side effects, making them attractive to both patients and healthcare providers.
• Personalized Treatment Approaches: The shift towards personalized medicine provides an opportunity for companies to develop treatments that are tailored to individual patient needs. By incorporating genetic and phenotypic data into treatment plans, pharmaceutical companies can offer more effective therapies, leading to improved patient outcomes.
• Improving Patient Education and Awareness: Expanding education and awareness about urinary incontinence can drive growth in the market. By educating both healthcare providers and patients about the available treatments, pharmaceutical companies can encourage earlier diagnosis and better management, increasing demand for urinary incontinence drugs.
• Advancements in Combination Therapies: The development of combination therapies that address multiple symptoms of urinary incontinence presents an opportunity for market expansion. These treatments can provide better symptom control and more comprehensive management, appealing to patients who require multifaceted treatment options.

Strategic growth opportunities in the urinary incontinence drug market, including expansion into emerging markets, innovative drug delivery systems, personalized treatments, patient education, and combination therapies, are reshaping the market. These opportunities provide avenues for pharmaceutical companies to meet the evolving needs of patients and drive sustained growth in the market.

Urinary Incontinence Drug Market Driver and Challenges

The urinary incontinence drug market is driven by advancements in treatment options, increasing awareness, and aging populations. However, it faces challenges such as high treatment costs, regulatory hurdles, and issues with drug adherence. Understanding these drivers and challenges is crucial for stakeholders looking to succeed in this evolving market.

The factors responsible for driving the urinary incontinence drug market include:

1. Technological Advancements in Treatment Options: New drug classes, such as beta-3 agonists, and the development of non-oral delivery systems are driving the market. These advancements offer better efficacy, fewer side effects, and improved patient compliance, contributing to the growth of the urinary incontinence drug market.

2. Growing Aging Population: As the global population ages, the prevalence of urinary incontinence increases, driving demand for effective treatments. This demographic shift is one of the primary factors driving market growth, particularly in developed countries with aging populations.

3. Increased Awareness and Diagnosis: As awareness of urinary incontinence rises, more individuals are seeking diagnosis and treatment. This increased awareness is expanding the market for urinary incontinence drugs, as more patients are actively managing their condition.

4. Regulatory Support for New Treatments: The introduction of new treatments and the increasing speed of regulatory approvals are driving the market. Favorable regulatory conditions allow pharmaceutical companies to bring innovative drugs to market more quickly, benefiting both patients and the industry.

5. Focus on Quality of Life: There is an increasing focus on improving the quality of life for patients with urinary incontinence. Pharmaceutical companies are prioritizing drug formulations that reduce side effects and provide better symptom control, which drives market growth by improving patient satisfaction.

Challenges in the urinary incontinence drug market are:

1. High Treatment Costs: The high cost of medications, especially newer biologic or advanced therapies, remains a barrier to access. This can limit the market potential, particularly in developing countries where affordability is a key issue.

2. Regulatory Challenges: Navigating complex regulatory landscapes, especially in emerging markets, presents a challenge. Strict regulations and long approval timelines can delay the availability of new treatments and limit market growth.

3. Drug Adherence Issues: Ensuring that patients adhere to their prescribed regimens is a major challenge. Side effects and the need for frequent dosing can lead to poor adherence, undermining the effectiveness of treatment and hindering market growth.

Drivers such as technological advancements, an aging population, increased awareness, and regulatory support are fueling market growth, while challenges such as high costs, regulatory hurdles, and drug adherence issues need to be addressed. These factors will shape the future of the urinary incontinence drug market, influencing both opportunities and obstacles for stakeholders.

List of Urinary Incontinence Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies urinary incontinence drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the urinary incontinence drug companies profiled in this report include-

• Pfizer
• Astellas Pharma
• Allergan
• Merck & Co.
• Sanofi
• Medtronic
• Mylan

Urinary Incontinence Drug Market by Segment

The study includes a forecast for the global urinary incontinence drug market by type, application, and region.

Urinary Incontinence Drug Market by Type [Value from 2019 to 2031]:

• Antispasmodic Agents
• Skeletal Muscle Relaxants
• Alpha Blockers
• Others

Urinary Incontinence Drug Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Urinary Incontinence Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Urinary Incontinence Drug Market

The urinary incontinence drug market has experienced substantial growth, driven by increasing awareness, aging populations, and innovations in treatment options. Countries such as the United States, China, Germany, India, and Japan have seen significant developments in both the availability of medications and therapeutic approaches, making strides in improving the quality of life for individuals suffering from urinary incontinence.

• United States: The United States has seen a rise in novel drug therapies for urinary incontinence, especially those targeting overactive bladder (OAB) and stress urinary incontinence (SUI). Recently, the approval of new pharmacological treatments such as mirabegron and novel formulations of anticholinergics has advanced the market. There is also a growing focus on patient-centered care and personalized treatment plans for better outcomes.
• China: In China, the urinary incontinence drug market is expanding rapidly, with an increasing number of patients seeking treatment due to a growing awareness of the condition. New drug approvals and partnerships between local and international pharmaceutical companies are enhancing access to advanced medications. However, challenges such as high drug costs and limited access to specialized treatments remain prevalent.
• Germany: German health infrastructure is well prepared to treat urinary incontinence, and new therapeutic combinations that include both pharmacological and non-pharmacological treatments have driven the market for urinary incontinence drugs. Combination therapies are found to be more effective in many cases, and reimbursement for new treatments has boosted the growth of this market.
• India: The urinary incontinence drug market in India is increasing because of increased awareness and a change in the preference to treat the elderly with incontinence. However, affordability is still a constraint. While anticholinergics remain the market leaders, newer beta-3 agonists are gaining ground, thereby providing more options for patients. Availability of health care services and awareness about treatment are crucial to the growth of the market.
• Japan: Japan has been at the forefront of urinary incontinence treatment innovation, with newer medications being introduced, particularly for overactive bladder. The focus is on improving drug efficacy while minimizing side effects. Japanese pharmaceutical companies are investing in novel drug formulations and combination therapies to meet the needs of a rapidly aging population, fueling market expansion.

Features of the Global Urinary Incontinence Drug Market

Market Size Estimates: Urinary incontinence drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Urinary incontinence drug market size by type, application, and region in terms of value ($B).

Regional Analysis: Urinary incontinence drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the urinary incontinence drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the urinary incontinence drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the urinary incontinence drug market by type (antispasmodic agents, skeletal muscle relaxants, alpha blockers, and others), application (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Urinary Incontinence Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Urinary Incontinence Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Urinary Incontinence Drug Market by Type
  • 3.3.1: Antispasmodic Agents
  • 3.3.2: Skeletal Muscle Relaxants
  • 3.3.3: Alpha Blockers
  • 3.3.4: Others
• 3.4: Global Urinary Incontinence Drug Market by Application
  • 3.4.1: Hospital Pharmacies
  • 3.4.2: Retail Pharmacies
  • 3.4.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Urinary Incontinence Drug Market by Region
• 4.2: North American Urinary Incontinence Drug Market
  • 4.2.1: North American Market by Type: Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, and Others
  • 4.2.2: North American Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.3: European Urinary Incontinence Drug Market
  • 4.3.1: European Market by Type: Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, and Others
  • 4.3.2: European Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.4: APAC Urinary Incontinence Drug Market
  • 4.4.1: APAC Market by Type: Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, and Others
  • 4.4.2: APAC Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.5: ROW Urinary Incontinence Drug Market
  • 4.5.1: ROW Market by Type: Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, and Others
  • 4.5.2: ROW Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Urinary Incontinence Drug Market by Type
  • 6.1.2: Growth Opportunities for the Global Urinary Incontinence Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Urinary Incontinence Drug Market by Region
• 6.2: Emerging Trends in the Global Urinary Incontinence Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Urinary Incontinence Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Urinary Incontinence Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Astellas Pharma
• 7.3: Allergan
• 7.4: Merck & Co.
• 7.5: Sanofi
• 7.6: Medtronic
• 7.7: Mylan